Liver/Biliary Disorders News

In a Healio video exclusive, Andreas Kremer, MD, PhD, MHBA, highlights recent data on primary biliary cholangitis presented at EASL Congress, including risk factors for disease progression and seladelpar for treatment of pruritus.

The first half of 2023 has already seen landmark FDA decisions in the gastroenterology space, including multiple first-in-class therapies along with two costly rejections that highlight persistent gaps in the GI drug armory.

Failure to achieve sustained virological response and the presence of more advanced chronic liver disease were associated with mortality in patients with hepatitis C and hepatocellular carcinoma, according to a researcher at EASL Congress.

In patients with idiosyncratic drug-induced liver injury, previous history of an allergic reaction related to drugs correlated with worse clinical outcomes, including death, according to data presented at the EASL Congress.

Topline findings from the phase 3 ELATIVE trial showed that elafibranor improved cholestasis response in patients with primary biliary cholangitis, Ipsen and Genfit announced.

Xarelto improved portal hypertension complication-free survival in patients with cirrhosis and moderate liver dysfunction without an increase in major bleeding events, according to data presented at the EASL Congress.

Mycophenolate mofetil was superior to azathioprine in achieving biochemical remission in treatment-naive patients with autoimmune hepatitis who were also treated with prednisolone, according to data presented at EASL Congress.

Treatment with lonafarnib boosted with ritonavir, with or without peginterferon alfa, resulted in significant virological and biochemical response in patients with chronic hepatitis D virus infection, according to data presented.

The ACG has created a new clinical guideline based on existing data and expert opinion to aid clinicians in the diagnosis and management of patients with acute liver failure, with a focus on specific etiologies and disease presentation.

Chronic hepatitis B virus infection was significantly associated with an increased risk for intracerebral hemorrhage but not other types of stroke in Chinese adults, according to data presented at the EASL Congress.